Home
ReportReportThe NHS has announced it will expedite a pioneering therapy for treating graft versus host disease. Cancer patients who have received crucial stem cell transplants now have renewed hope in the fight against chronic graft versus host disease. NHS England plans to introduce Belumosudil (Rezurock®), a medication specifically developed to combat this uncommon but severe complication.
This announcement aligns with Rare Disease Day, which brings attention to over 7,000 rare diseases affecting approximately 3.5 million individuals in the UK.
The inclusion of Belumosudil in the NHS Innovative Medicines Fund marks a significant step forward in the treatment of rare diseases.
As the fourth treatment to be accelerated through this program, following a therapy for Wolman disease last year, it emphasizes the importance of speeding up access to transformative treatments for patients with complex health issues.
James Palmer, NHS England’s Medical Director for Specialised Services, stated that this rollout represents a significant advancement for patients with graft versus host disease. He noted that it would assist individuals living with this debilitating condition in managing their symptoms more effectively, thereby improving their quality of life and daily functioning. Palmer highlighted the positive impact of the NHS’s ability to fast-track funding for a treatment that would benefit hundreds of patients in the years to come.
Digital twins come with many benefits that impact multiple segments Digital twins create a simulated model of a patient that reflects his or her individual conditions and responses, allowing for personalized treatments and a move away from the trial-and-error practice that can dominate medicine. This enhances success rates and reduces adverse effects.
Usamos cookies para mejorar su experiencia de navegación, mostrarle anuncios o contenidos personalizados
Toronto, Canada – NuraLogix, a global pioneer in Affective Ai and the developer of the most widely recognized of the contactless blood pressure app, has today announced the latest evolution of its groundbreaking Anura® MagicMirror™. Now equipped with 4G connectivity and...
C8 Health, the clinical resource management platform designed for healthcare providers, is pleased to announce a partnership with the Society for Obstetric Anesthesia and Perinatology (SOAP) to bring the C8 Health platform to SOAP members. Through this partnership, C8 Health will provide SOAP members with an exclusive version of the C8 Health app available for smartphones, tablets, and desktops.
Chronic disease management involves coordinating care for long-term health conditions such as asthma, diabetes, and hypertension. Effective management can help prevent complications, improve patients' quality of life, and reduce hospital admissions.
Healthcare systems worldwide are facing an increasing burden from lifestyle-related diseases like obesity and diabetes. Public health strategies that promote healthier living and prevent these conditions can help reduce healthcare costs and improve quality of life.
